The Prognostic Role of the Neutrophil-to-Lymphocyte Ratio in Oropharyngeal Carcinoma Treated with Chemoradiotherapy by Young, CA et al.
81CliniCal MediCine insights: OnCOlOgy 2014:8
Open Access: Full open access to 
this and thousands of other papers at 
http://www.la-press.com.
Clinical Medicine Insights: 
Oncology
Introduction
Concurrent chemoradiotherapy (CRT) is a standard organ-
preserving approach for patients with locally advanced oropha-
ryngeal cancers.1 Human papilloma virus (HPV)-related 
oropharyngeal squamous cell carcinomas are associated with 
a more favorable prognosis compared with HPV-negative 
disease.2 Treatment regimens for oropharyngeal carcinoma 
are associated with significant early and long-term toxicity.3 
There is considerable interest in the development of additional 
prognostic biomarkers to allow the stratification of treat-
ment intensity according to prognosis. The identification of a 
robust favorable prognosis group would allow investigation of 
approaches testing a de-escalation of treatment intensity with 
the aim of maintaining cure rates whilst reducing toxicity; 
conversely, studies of treatment intensification may be consid-
ered in patients with a poorer prognosis.
Host-related factors including performance status, weight 
loss, smoking, comorbidity, in addition to tumor pathology, 
play an important role in cancer outcomes.4 It has become evi-
dent that the cancer-associated systemic inflammatory response 
has an important influence on disease-related outcomes 
for many cancer sites.5,6 Systemic inflammatory responses 
are associated with alterations in circulating white blood 
cell counts, with a neutrophilia and relative lymphopenia.7 
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The neutrophil-to-lymphocyte ratio (NLR), a biomarker of 
the host systemic inflammatory response, has been shown to 
be highly promising in stratifying outcome in large cohorts 
of patients with cancers arising from unselected sites, with 
a higher pre-treatment ratio associated with a poorer prog-
nosis.8,9 Other components of the systemic inflammatory 
response including platelet counts, albumin and C-reactive 
protein (CRP) levels are prognostically important in some 
studies.10 The platelet-to-lymphocyte ratio (PLR) is prognos-
tically important in some tumor sites.11,12
There is a paucity of data with regard to the prognostic 
influence of the systemic inflammatory response in head and 
neck cancers. This is further complicated by the range of ana-
tomical tumor sites and treatment approaches within the head 
and neck region. Here, we report the outcomes of patients with 
oropharyngeal carcinoma treated with concurrent-chemora-
diotherapy and examine the prognostic influence of biomark-
ers of the host systemic inflammatory response including the 
NLR and PLR.
Methods
study design. A total of 249 consecutive patients with 
oropharyngeal squamous cell carcinoma treated with radical 
chemo-radiotherapy with curative intent between January 
2004 and December 2010 at St. James’s Institute of Oncology, 
Leeds, UK were retrospectively identified using electronic 
databases. Inclusion criteria for the current study were: his-
tologically proven squamous cell carcinoma, oropharyngeal 
primary site, treatment with curative intent, documented 
intention to treat with concurrent chemoradiotherapy ± 
induction chemotherapy. Exclusion critieria were: local or 
regional surgery prior to chemoradiotherapy, unavailability of 
pre-chemotherapy blood results. Full blood counts were rou-
tinely measured at St. James’s Institute of Oncology prior to 
treatment. Pre-treatment hemoglobin, albumin, neutrophil, 
lymphocyte, and platelet counts were recorded from routine 
blood counts. NLR and PLRs were calculated. Tumor-node-
metastasis (TNM) staging was routinely recorded in case 
notes according to the American Joint Committee on Cancer 
(AJCC) classification 2002 edition.
Induction chemotherapy. Induction chemotherapy 
was used based upon clinician preference, patient and tumor 
factors; in general induction chemotherapy was consid-
ered for patients with bulky disease. Regimens consisted of 
2–4 cycles of cisplatin 80 mg/m2 day 1 and 5-fluorouracil 
(5-FU) 800 mg/m2 days 2–5, three times weekly.13 From 
2006, docetaxel 75 mg/m2 day 1, cisplatin 75 mg/m2 day 1, 
and 5-FU 750 mg/m2 days 2–5, three times weekly was avail-
able for selected fit patients.14
concurrent chemotherapy. Patients ,70 years old were 
considered for concurrent chemotherapy. Standard concurrent 
chemotherapy was cisplatin 100 mg/m2 days 1 and 29. Carbo-
platin AUC 4 was substituted for cisplatin if creatinine clear-
ance was ,55 mL/min.
radiotherapy. The majority of the patients in this study 
were treated with a two-phase conformal technique of two 
lateral parallel opposed 6 MV photon fields with multiple 
field-in-fields, with a matched anterior neck field and pos-
terior electron fields, as previously described.14 The clini-
cal target volume included primary site and bilateral level 
Ib, II, III, IV, and V lymph nodes. Retropharyngeal lymph 
nodes were variably included depending upon tumor site and 
stage. Conventionally fractionated intensity modulated radio-
therapy (IMRT) was used to treat patients from late 2009; 
target volume delineation was based upon a compartmental 
approach previously described for oropharyngeal cancer in the 
UK parotid sparing oropharynx trial.15 IMRT was delivered 
with a 5–7 angle step and shoot IMRT technique. Standard 
dose during this period was 70 Gy in 35 fractions, with alter-
nate regimens used at clinician discretion.
response assessment and follow-up. Tumor response 
was routinely assessed 3–4 months after the completion of the 
treatment. Response assessment routinely included clinical 
examination, panendoscopy, and imaging (CT, MRI, and/or 
PET-CT). Examination under anesthetic and biopsies were 
performed in the event of any clinical or radiological suspicion. 
A neck dissection was considered only if there was an incom-
plete nodal response. Subsequently, patients were followed up 
with physical examination every 6–8 weeks in the first year 
after treatment, every 3 months for an additional 2 years, and 
every 6 months until discharge at 5 years.
statistical analysis. Time elapsed to treatment failure 
or death was calculated using the first day of treatment as 
the starting point. Local and regional controls were defined 
as no evidence of recurrence or progression of the primary 
tumor and neck lymph nodes, respectively. Distant control 
was defined as the absence of distant metastases. In the over-
all survival estimates, deaths due to all causes are included 
in the calculations. For the purposes of analysis, an NLR of 
$5 is allocated a score of 1, and ,5 a score of 0. A PLR of 
150 is given a score of 0, 150 and 300 a score of 1, and 
a score 300 is given a score 2. Univariate and multivariate 
Cox regression (backward elimination based on a likelihood 
ratio test) analyses were performed for each endpoint. The fol-
lowing factors were included in the multivariate model: age, 
gender, smoking status, tumor grade, T stage, N stage, use of 
induction chemotherapy, number of concurrent chemotherapy 
cycles, albumin, NLR, and PLR. Statistical significance was 
declared at P , 0.05. Analysis was performed using SPSS 
software (Version 19.0.0. SPSS Inc., Chicago, IL, USA).
results
A total of 251 patients with oropharyngeal squamous cell car-
cinoma treated with concurrent chemoradiotherapy ± induc-
tion chemotherapy were identified. Two patients were excluded 
as blood results were unavailable; no patients with active sys-
temic inflammation were identified. Median follow-up for 
living patients was 46 months (range 9–98). Demographics 
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and patient characteristics (Table 1) and treatment details are 
analyzed (Table 2).
survival outcomes and the role of the nlr and Plr. 
The 3 year overall survival, local control, regional control, and 
distant control were 70%, 85%, 87%, and 87%, respectively. 
Univariate analysis was performed for the following factors: 
gender, grade, T stage, N stage, number of cycles of concur-
rent chemotherapy, use of induction chemotherapy, NLR 
(,5 versus 5), PLR (150 versus 150 versus 300), and 
smoking status (Table 3). Kaplan–Meier curves illustrating 
the disease outcomes stratified by a NLR of 5 and 5 based 
on univariate analysis are shown in Figure 1. Multivariate 
analysis was performed including the following factors in the 
multivariate model: age, gender, smoking status, tumor grade, 
T stage, N stage, use of induction chemotherapy, number of 
concurrent chemotherapy cycles, albumin, NLR, and PLR 
(Table 4). Statistically significant prognostic factors for local 
control were T stage (P = 0.003) and the NLR (P = 0.009), for 
regional control the NLR (P = 0.009), for loco-regional con-
trol T stage (P = 0.002) and the NLR (P = 0.023), for distant 
control T stage (P = 0.021), and for overall survival T stage 
(P = 0.001) and grade (P = 0.048). The PLR was not signifi-
cantly associated with any disease or survival outcomes on the 
multivariate analysis.
discussion
The systemic inflammatory response appears to be associated 
with poorer cancer survival independent of tumor stage in 
multiple tumor sites.4,6 Several biochemical and hematologi-
cal parameters, including white blood cells, neutrophil and 
platelet counts, albumin, and CRP levels, have been examined 
as possible biomarkers for a systemic inflammatory response.4 
The NLR is one of the most promising biomarkers, being 
shown to stratify outcome in a host of tumor sites, includ-
ing gastro-esophageal, pancreatic, lung, colorectal, renal, and 
breast tumors.5,16 The prognostic influence of the NLR has 
been reported in the context of a variety of treatments, includ-
ing surgery,17 neoadjuvant chemotherapy,18 chemotherapy,19 
radiotherapy,5 and during follow-up.20 Despite the hetero-
genous nature of the studies performed, the NLR has a con-
sistent prognostic impact, suggesting an association with more 
aggressive tumor biology.5
We report the analysis of the outcomes from our expe-
rience of managing a large cohort of patients with locally 
advanced oropharyngeal carcinoma with chemo-radiotherapy 
in relation to the prognostic influence of biomarkers of the 
host inflammatory response. On multivariate analysis, a raised 
NLR was associated with poorer local and regional control. 
Although there was an association with distant control and 
overall survival on univariate analysis (Fig. 1), this was not 
Table 1. Patient demographics and disease characteristics.
NumbeR (%) 
(TOTaL = 249)
Male
Female
200 (80.3%)
49 (19.7%)
Age (median (range)) 55 (31–78)
smoking
never
ex/current
not recorded
71 (28.5%)
166 (66.7%)
12 (4.8%)
Primary tumour site:
tonsil
Base of tongue
soft Palate
Oropharynx, not classified
154 (61.3%)
82 (32.9%)
8 (3.2%)
5 (2.0%)
t stage
tX
t1
t2
t3
t4
1 (0.4%)
47 (18.9%)
70 (28.1%)
37 (14.9%)
94 (37.8%)
n stage
n0
n1
n2a
n2b
n2c
n3
25 (10.0%)
28 (11.2%)
31 (12.4%)
87 (34.9%)
54 (21.7%)
24 (9.6%)
grade
Well differentiated
Moderately differentiated
Poorly/undifferentiated
Unclassified
12 (4.8%)
68 (27.3%)
133 (53.4%)
36 (14.5%)
Table 2. treatment details.
NumbeR (%) 
(TOTaL = 249)
induction chemotherapy
none
Docetaxel/cisplatin/5-fluorouracil
Cisplatin or carboplatin with 5-fluorouracil
Other
95 (38.2%)
55 (22.1%)
96 (38.6%)
3 (5.2%)
Concurrent chemotherapy
Cisplatin
Carboplatin
Planned but not given after induction chemotherapy
216 (86.7%)
21 (8.4% )
12 (4.8%)
no. Cycles concurrent chemotherapy
0
1
2
3
12 (4.8%)
70 (28.1%)
145 (58.2%)
22 (8.8%)
Radiation dose
70 gy in 35 fractions
68 gy in 34 fractions
66 gy in 33 fractions
65 gy in 30 fractions
56 gy in 20 fractions
not received 
186 (74.7%)
13 (52.2%)
8 (3.2%)
19 (7.6%)
21 (8.4%)
2 (0.8%)
neutrophil-to-lymphocyte ratio pre-treatment
5
5
Missing data
196 (78.7%)
50 (20.1%)
3 (1.2%)
Platelet-to-lymphocyte ratio pre-treatment
150
150300
300
Missing data
109 (43.8%)
116 (46.6%)
21 (8.4%)
3 (1.2%)
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Table 3. Univariate analysis.
LOCaL  
CONTROL*
RegiONaL  
CONTROL*
LOCORegiONaL  
CONTROL*
diSTaNT  
CONTROL*
dfS (iNCLudeS  
deaTh aS eveNT)
OS
P value
gender
M vs F
0.450 0.115 0.113 0.579 0.331 0.213
grade
1/2 vs 3
0.150 0.905 0.106 0.366 0.04 0.017
t stage
1/2 vs 3/4
0.000 0.174 0.000 0.020 0.000 0.000
n stage
0/1 vs 2/3
0.718 0.089 0.775 0.550 0.4290 0.226
no. concurrent cycles  
of chemotherapy
0/1 vs 2/3
0.099 0.249 0.149 0.605 0.117 0.133
induction chemotherapy
none vs induction
0.019 0.028 0.011 0.568 0.602 0.957
nlR
,5 vs $ 5
0.000 0.019 0.001 0.042 0.012 0.017
PlR
150 vs 150 vs 300
0.073 0.894 0.457 0.520 0.187 0.043
smoking status
non-smoker vs ex/current
0.207 0.146 0.113 0.012 0.043 0.053
Note: *death not included as event.
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figure 1. Kaplan–Meier curves showing (a) local control, (b) regional control, (C) distant control, and (d) overall survival, according to a NLR  
of 5 or 5. P values are those from univariate analysis.
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significant on multivariate analysis. The PLR and albumin 
levels were not prognostically significant.
There is considerable heterogeneity of the NLR threshold 
utilized in reported series. Drawing conclusions based upon 
the use of varied NLR cut-offs is challenging. A significant 
majority of studies have used a threshold ratio of 5, and it 
has been recommended that future work should use this most 
commonly used threshold.5 Therefore, for the purpose of this 
study, we have used a threshold of 5. For similar reasons, we 
have utilized PLR thresholds commonly used elsewhere.21
In this study, pre-treatment variables have been analyzed 
in relation to outcome measures. Pre-treatment prognostic vari-
ables are of potential clinical importance in guiding decision 
making. We have not performed a similar analysis based upon 
blood counts acquired during treatment with either induction 
chemotherapy or concurrent chemotherapy. Such an analysis 
would have been of little value in our historical retrospective 
cohort as blood tests were not performed at consistent time 
points. In addition, the use of varied induction chemotherapy 
regimens for a significant proportion of patients would limit 
useful analysis. It therefore remains unclear as to whether 
NLR or PLR variables acquired during treatment have any 
prognostic significant. However, it might be expected that the 
bone marrow suppressive effect of chemotherapy with sub-
sequent influence on NLR and PLR values would confound 
with any relationship with outcome measures.
The main limitation of this study is that we do not have 
HPV data available for this large retrospective cohort dating 
back to 2004. HPV-related oropharyngeal cancers typically 
occur in younger patients with less smoking history, are gener-
ally histopathologically poorly differentiated, and carry a more 
favorable prognosis with a 3 year survival of 82 versus 57% in 
the series reported by Ang et al.2 The influence of the NLR ratio 
upon outcome was present despite the inclusion of tumor grade 
and smoking status in the multivariate analysis. The relation-
ship between the NLR and HPV status remains uncertain.
CRP levels have been combined with albumin levels into 
the modified Glasgow prognostic score as an index of the sys-
temic inflammatory condition.6 We do not routinely check 
CRP levels prior to chemo-radiotherapy; therefore, it was not 
possible to analyze the prognostic value of this variable.
The NLR was not associated with distant control or 
overall survival on multivariate analysis. However, as shown 
in Figure 1, on univariate analysis, poorer outcomes were sig-
nificantly associated with raised NLRs for these outcomes. 
The loss of statistical significance on multivariate analysis may 
result from the limited number of events in this sample size.
There is only limited data exploring the role of the sys-
temic inflammatory response in head and neck cancer. Markers 
of the systemic inflammatory response in patients with head 
and neck cancer have not been compared to the normal popu-
lation or to patients with non-malignant inflammatory condi-
tions. The prognostic relevance of these biomarkers has not 
been previously reported in a cohort of oropharyngeal cancer 
patients. However, these findings are consistent with several 
other observations in head and neck cancer patients. One 
recent retrospective study of 273 patients with head and neck 
squamous cell cancers (including non-oropharyngeal sites) 
over a 10 year period and treatment approaches has reported 
that the PLR was an independent predictor of mortality and 
the NLR an independent predictor of recurrence.12 A raised 
NLR has been associated with a poorer prognosis in patients 
with nasopharyngeal carcinoma.22 Similarly, markers of blood 
leukocyte activation have been linked to survival in head and 
neck cancer.23 An important role for the host inflammatory 
response is also implied by one study demonstrating that 
elevated CRP levels were associated with poorer outcomes in 
operable oral squamous cell carcinoma.24
In multiple tumor types, the NLR appears to be related 
to more advanced disease stage and possible more aggres-
sive tumor behavior.5 The underlying mechanism is unclear, 
although elements of the innate inflammatory response have 
been associated with upregulation of growth factors, angio-
genesis, impaired cellular immunity, and cancer cachexia.4–6 
Recent studies have found increased levels of pro-inflammatory 
cytokines in patients with an elevated NLR25,26 and an 
increased peri-tumor macrophage infiltration.25 These data 
suggest that a raised NLR reflects an up-regulated innate 
immune response.5 In addition to these data suggesting a role 
for the innate immune system in influencing the prognosis of 
oropharyngeal cancer, evidence is accumulating a role for the 
adaptive immune response. Ward et al recently showed that 
high levels of tumor infiltrating lymphocytes could stratify the 
prognosis of HPV-positive oropharyngeal cancers into high 
and low risk groups.27 In common with other tumor sites, it is 
becoming increasingly clear that both the innate and adaptive 
arms of the immune system appear to have a key role in influ-
encing the behavior and outcome of head and neck cancers.28
Table 4. Multivariate analysis.
vaRiabLe hazaRd  
RaTiO
95% CONfideNCe  
iNTeRvaL
p vaLue
Local control
t stage 3/4 vs 1/2 3.958 1.609–9.736 0.003
nlR $ 5 vs ,5 2.516 1.262–5.017 0.009
Regional control
nlR $ 5 vs ,5 2.762 1.286–5.933 0.009
Locoregional control
t stage 1/2 vs 3/4 3.263 1.536–6.929 0.002
nlR ,5 vs $ 5 2.072 1.105–3.886 0.023
distant control
t stage 3/4 vs 1/2 2.959 1.181–7.416 0.021
Overall survival
grade 3 vs 1/2 0.613 0.378–0.995 0.048
t stage 3/4 vs 1/2 2.474 1.453–4.210 0.001
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conclusion
In summary, the host systemic inflammatory response 
has been hypothesized to have an important role in can-
cer outcomes across a wide range of tumor sites. The NLR 
is a potential biomarker of the innate immune response. 
We retrospectively analyzed the outcomes of 249 patients 
with oropharyngeal carcinoma treated between 2004 and 
2010 with concurrent chemoradiotherapy ± induction che-
motherapy. The NLR was an independent prognostic fac-
tor for local and regional control. Further validation is 
required prior to incorporating the NLR into prognostic 
stratification.
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